Purpose: We characterized the location and spatial distribution of whole body pain in patients with urological chronic pelvic pain syndrome using a body map. We also compared the severity of urinary symptoms, pelvic pain, nonpelvic pain and psychosocial health among patients with different pain patterns. Materials and Methods: A total of 233 women and 191 men with urological chronic pelvic pain syndrome enrolled in a multicenter, 1-year observational study completed a battery of baseline measures, including a body map describing the location of pain during the last week. Participants were categorized with pelvic pain if they reported pain in the abdomen and pelvis only. Participants who reported pain beyond the pelvis were further divided into 2 subgroups based on the number of broader body regions affected by pain, including an intermediate group with 1 or 2 additional regions outside the pelvis and a widespread pain group with 3 to 7 additional regions. Results: Of the 424 enrolled patients 25% reported pelvic pain only and 75% reported pain beyond the pelvis, of whom 38% reported widespread pain. Participants with a greater number of pain locations had greater nonpelvic pain severity (p <0.0001), sleep disturbance (p ¼ 0.035), depression (p ¼ 0.005), anxiety (p ¼ 0.011), psychological stress (p ¼ 0.005) and negative affect scores Accepted for publication March 23, 2017. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
(p ¼ 0.0004), and worse quality of life (p 0.021). No difference in pelvic pain and urinary symptom severity was observed according to increasing pain distribution. Conclusions: Three-quarters of the men and women with urological chronic pelvic pain syndrome reported pain outside the pelvis. Widespread pain was associated with greater severity of nonpelvic pain symptoms, poorer psychosocial health and worse quality of life but not with worse pelvic pain or urinary symptoms.
Key Words: urinary bladder; prostate; cystitis, interstitial; prostatitis; pelvic pain PATIENTS with IC/BPS or CP/CPPS commonly report nonurological symptoms or syndromes outside the pelvic region. There are also associations among IC/ BPS, CP/CPPS and COPCs such as irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome 1e3 with some studies showing systemic (eg polysymptomatic and polysyndromic) symptom presentations. 4, 5 It has been hypothesized that patients with localized pelvic pain might represent a different phenotype than those with more widespread systemic pain. 6, 7 However, to date few studies have characterized the location of body pain in men and women with IC/BPS or CP/CPPS.
FitzGerald et al first reported that 11% of patients in the IC Database Study had other pain (eg whole body, 1 side, eyes or kidney). 8 Tripp et al used a whole body diagram to characterize the location of pain in female patients with IC/BPS. 6 They found that as the number of body pain sites increased, patients experienced greater sensory and affective pain, higher depression scores and diminished quality of life. Nickel et al found that female patients with IC/BPS who had pelvic pain and beyond also reported greater sleep disturbance and a higher prevalence of irritable bowel syndrome than female patients with IC/BPS who had pelvic pain only. 7 Although these studies suggest the existence of distinct clinical subtypes in female patients, to our knowledge similar studies have not yet been performed in men and no group has examined the concept of widespread body pain in men or women. Findings in other chronic pain conditions suggest that patients with widespread pain have centralized pain characteristics. 9e15 We report the body pain mapping results of the MAPP Research Network in a large cohort of men and women with UCPPS. 16 UCPPS is an umbrella term used to describe IC/BPS in men and women, and CP/CPPS in men. To our knowledge this is the largest body pain mapping study of UCPPS to date.
Study objectives were to 1) characterize the location of pain among men and women with UCPPS using a body map, 2) test the hypothesis that patients with UCPPS and widespread pain have worse urinary symptoms, more severe pain and poorer psychosocial health than those with more localized pain and 3) examine whether an increased pain distribution is associated with a longer duration of UCPPS symptoms.
METHODS Participants
The MAPP Research Network enrolled 191 men and 233 women with UCPPS at a total of 6 clinical sites across the United States. The study design, and inclusion and exclusion criteria have been described previously. 17 To meet IC/BPS symptom criteria males and females had to report an unpleasant sensation of pain, pressure or discomfort that was perceived to be related to the bladder and/or pelvic region and associated with lower urinary tract symptoms for most of the time during the most recent 3 months. Males who met CP/CPPS criteria had to report pain or discomfort in any of the 8 male GUPI domains and these symptoms had to have been present for most of the time during any 3 of the previous 6 months. 18 Participants provided written informed consent according to institutional review board approved protocols. Figure 1 shows the body map originally described by Margolis et al, 19 which was used in 2 previous IC/BPS studies. 6, 7 Participants were asked to check any of 45 body sites on the body map where they had experienced pain in the last week. Participants who reported pain at sites 14, 15 or 16 only were considered to have pelvic pain only. 7 Participants who reported pain in any of the 7 broader body regions in addition to sites 14, 15 or 16 were considered to have pelvic pain and beyond. Our pelvic pain only vs pelvic pain and beyond nomenclature was similar to that in a previous mapping study by Nickel et al. 7 The pelvic pain and beyond group was further divided into 2 subgroups, including an intermediate group with 1 or 2 additional pain regions outside the pelvis and the widespread pain group with 3 to 7 additional pain regions outside the pelvis ( fig. 1 ). The threshold for widespread pain was operationalized to divide participants with pelvic pain and beyond into 2 subgroups with approximately equal numbers of patients.
Pain Assessment

Measures
MAPP Network questionnaires have been described previously. 17 Urological measures included ICSI, ICPI, GUPI, the AUA symptom index, the RICE (RAND Interstitial Cystitis Epidemiology) instrument to assess bladder hypersensitivity, 20 numerical ratings of pelvic pain, frequency or urgency, the MAPP Composite Pelvic Pain Score and Composite Urinary Score, and UCPPS flare assessment. 21 Nonurological and psychosocial measures included a numerical rating from 0 to 10 for nonurological or nonpelvic pain, fulfillment of standardized criteria of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, migraine headache or vulvodynia using CMSI modules, 22 BPI for overall pain severity and pain interference, HADS for anxiety and depression, PANAS, PSS for psychological stress, CSQ for pain catastrophizing, CMSI for somatic symptom burden and PROMIS scales for fatigue and sleep disturbance. Quality of life measures included SF-12Ò and GUPI. We limited our analyses to cross-sectional baseline data in this study.
Statistical Analyses
Less than 5% of data were missing on the reported outcomes. No imputations or adjustments were performed and missing data were excluded from analysis. The mean AE SD is reported for continuous variables and relative frequencies are reported for categorical variables. To test for a linear gradient effect in the 3 groups an ordinal value was assigned to each group, including 2dwidespread pain, 1dintermediate pelvic pain and beyond, and 0dpelvic pain only. The nonparametric Jonckheere-Terpstra trend test was used to analyze the ordered progression of the measure across the 3 groups. 23 Analyses were done with SASÒ, version 9.4.
RESULTS
Pain Localization Patterns and Urological Chronic Pelvic Pain Syndrome Symptom Duration Only 25.5% of patients with UCPPS reported pelvic pain only while 74.5% reported pelvic pain and beyond. Table 1 lists the percent of men and women in the pelvic pain only, intermediate and widespread pain groups. Relative to men, women were more likely to experience more widespread pain (p trend ¼ 0.039). There were no differences in the duration of UCPPS symptoms among the 3 pain groups (table 1) . Heat maps were constructed to show the proportion of participants with pain at a specific location in each of the 3 pain groups ( fig. 2 ).
Pelvic Pain and Urinary Symptom Severity
Men and women demonstrated no difference in the severity of pelvic pain, urinary symptom features (frequency and urgency) and bladder hypersensitivity features (eg painful bladder filling and/or painful urgency) 20 among the 3 pain groups (p >0.05, table 1). Women with a greater number of pain locations were more likely to report higher GUPI pain scores (p ¼ 0.033) and symptom flare at the time of a visit (p ¼ 0.012).
Nonpelvic Pain Severity and Chronic Overlapping Pain Conditions
Men and women with a greater number of pain locations were more likely to report higher levels of nonpelvic pain severity (0 to 10 numerical ratings) and symptoms consistent with irritable bowel syndrome, fibromyalgia and migraine headache (p <0.05, table 2). Women with a greater number of pain locations were also more likely to report higher pain interference scores on BPI as well as symptoms consistent with chronic fatigue syndrome and multiple (2 or more) COPCs.
Psychosocial Health and Quality of Life
Men and women with a greater number of pain locations had greater sleep disturbance on PROMIS, depression and anxiety on HADS, psychological stress on PSS, a somatic symptom burden on CMSI and negative affect scores on PANAS (p <0.05, table 2). Women with a greater number of pain locations were also more likely to report pain catastrophizing on CSQ and fatigue on PROMIS as well as a decreased positive affect on PANAS. While the more general physical health and mental health domains of SF-12 deteriorated across the gradient of increasing pain distribution, no trend was noted for urinary specific quality of life on GUPI in men or women.
Comparison of 2 Subgroups with Pelvic Pain and Beyond
Individuals commonly report pain in parts of the body from time to time (eg more than 40% of participants reported back pain or headache). To determine whether patients in the intermediate group with a limited distribution of pain outside the pelvis had a different presentation than those with widespread pain we performed additional comparisons of the 2 subgroups (table 3) .
Men and women with widespread pain reported more severe nonpelvic pain and were more likely to have fibromyalgia, depression, higher psychological stress, a higher somatic symptom burden and worse physical health on SF-12 than men and women in the intermediate group. Men with widespread pain were additionally more likely to have migraine headache, anxiety, pain catastrophizing, a more negative affect and a less positive affect. Women with widespread pain were additionally more likely to have irritable bowel syndrome, chronic fatigue syndrome, multiple (2 or more) COPCs, sleep disturbance, fatigue and worse mental health on SF-12 than the respective intermediate group. In both genders there was no difference in pelvic pain and urinary symptom severity between the 2 subgroups.
DISCUSSION
Despite being enrolled because of UCPPS, 75% of patients in this large multisite study reported additional pain outside the pelvis/abdomen and 38% reported a widespread pain distribution. In men and women an increasing anatomical pain distribution was associated with greater nonpelvic pain severity, a higher prevalence of chronic overlapping pain conditions, poorer psychosocial health and worse quality of life. In contrast, there was no difference in the severity of pelvic pain and urinary symptoms among the 3 pain subgroups. Patients with UCPPS who had widespread pain appeared to be distinct from patients with a more limited distribution of pain outside the pelvis in the intermediate group (table 3) .
Our overall findings were consistent with those of previous studies. Women with IC/BPS and systemic pain were more likely to have more severe overall pain, other pain syndromes and worse quality of life than women who reported pelvic pain only. 6, 7 Previous body pain mapping studies did not include men. 6, 7 We studied a large cohort of men with IC/ BPS or CP/CPPS and found many similar findings in the 2 genders.
Body pain mapping may confer important information that suggests discrete UCPPS patient subgroups. Pain involving several body regions is likely to represent systemic pathophysiology characterized by centralized pain characteristics (eg driven by central sensitization and/or neuro-immune processes). Although the operational definitions of widespread pain have varied among studies, literature on other chronic pain conditions suggests that the subgroup of patients with widespread pain may have more severe pain, decreased pain thresholds and a centralized pain phenotype.
9e15 For instance, patients with temporomandibular disorders and widespread pain had reduced pressure pain thresholds in the cranial and extracranial regions compared to similar patients with more localized pain. 9 Patients with epicondylitis and patients at multidisciplinary pain clinics with widespread pain also had a lower pressure pain threshold or increased central sensitization compared to similar patients with localized pain. 10, 11 We report that a substantial proportion of patients with UCPPS have widespread pain and those with widespread pain have more intense whole body pain. Ongoing MAPP neuroimaging studies also suggest that patients with UCPPS and widespread pain have altered brain structure and function. 24, 25 In future studies we shall examine pain thresholds and quantitative sensory testing data in these patients.
Assessing the severity of pelvic pain, urinary symptoms (frequency and urgency) or bladder hypersensitivity (eg painful bladder filling and painful urgency) 20 alone cannot distinguish between the pelvic pain only group and the widespread pain group. Instead the body map might identify patients who may have a more centralized pain syndrome that is possibly related to central sensitization.
The body pain map may also be used to screen patients who may benefit from clinical evaluation for other COPCs. For example, among women with UCPPS in the widespread pain subgroup 48% had irritable bowel syndrome, 26% had fibromyalgia, 31% had chronic fatigue syndrome and 42% had migraine headaches. Among men with UCPPS in the widespread pain subgroup these rates were 34%, 13%, 5% and 24%, respectively. Women with widespread pain were more likely to have multiple (2 or more) COPCs. Although widespread pain is a cardinal component of fibromyalgia, it should be noted that relatively few patients with UCPPS and widespread pain met the criteria for fibromyalgia, including only 13% of men and 26% of women. 26 The difference is that besides widespread pain, fibromyalgia also requires other symptoms (eg fatigue and somatic symptoms).
The body pain map might also be used to screen for patients with a high psychosocial burden (depression, anxiety, psychological stress, negative affect and/or pain catastrophizing). The body pain map, which is simple to use ( fig. 1 ), can be included in the evaluation of IC/BPS and CP/CPPS.
Clinicians should consider performing clinical phenotyping to tailor treatment to patients with UCPPS. It is possible that body pain mapping may be to categorize the heterogeneous UCPPS population and it may inform more rational management strategies. For example, one might hypothesize that patients with bladder hypersensitivity features 20 and localized pelvic pain only may be more likely to benefit from bladder centric treatments (eg intravesical instillation or pentosan polysulfate). One might also hypothesize that UCPPS subpopulations with widespread pain might be less likely to benefit from bladder or pelvic directed treatments alone. They might require systemic therapies for centrally mediated mechanisms (eg using tricyclic antidepressants, gabapentinoids, serotonin-norepinephrine reuptake inhibitors or multidisciplinary pain management). Because many patients with widespread pain report increased psychosocial difficulties, they may also benefit from multimodal and multidisciplinary therapies.
Using a 1 size fits all approach to treat IC/BPS or CP/CPPS without regard for patient discrete clinical characteristics (eg localized vs systemic pain) and pathogenesis may lead to treatment failure. In part these hypotheses may explain why most prior randomized, controlled trials failed to demonstrate clinically significant benefits of treating the entire UCPPS population with similar therapies. This is an important area for future translational studies because currently no high level evidence (randomized controlled trials) supports this personalized approach to managing UCPPS. 27, 28 There are potential weakness in this study. 1) We did not collect data on tobacco abuse, musculoskeletal trauma, myofascial pain or medical conditions (eg osteoarthritis and rheumatoid arthritis) which may influence the distribution of pain.
2) It has been hypothesized that UCPPS might progress with time from localized pain to locoregional pain to systemic pain (eg central sensitization). 1, 4, 29 Our data as well as those of Nickel et al 7 did not show a correlation between the duration of UCPPS symptoms and an increased body pain distribution. However, we cannot infer a longitudinal trend from these crosssectional data (eg there are risks of recall bias). Longitudinal studies are needed to determine whether there is a temporal progression from one body pain pattern to another with time.
CONCLUSIONS
Three-quarters of the men and women with UCPPS (IC/BPS or CP/CPPS) reported pain outside the pelvis. Widespread pain was associated with greater severity of nonpelvic pain symptoms, poorer psychosocial health and worse quality of life but not with worse pelvic pain or urinary symptoms.
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